1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. SIONNA THERAPEUTICS INC.

Sionna Therapeutics Inc.

XNAS: SION

Download real time

9.97 -1.64 (-14.13%)

New 52W Low in past week

200.8K XNAS Volume

XNAS 04 Apr, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
3S
13W
1O
0T
438.6

Market Cap

Below industry Median
-

PE TTM

-

PEG TTM

-2.7

Price to Book

Negative Price to Book
-

Beta 1Year



Insider Trading disclosures for Sionna Therapeutics Inc.

The latest disclosure was made by Peter A. Thompson in Sionna Therapeutics Inc. where a trade of 3,154,959 Common Stock done was reported to US exchanges on Feb. 10, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Peter A. Thompson Director 10 Feb 2025 3,154,959 3,154,959 - - Common Stock
Bruce Booth Director 10 Feb 2025 1,298,332 0 - - Series B convertible preferred stock
Bruce Booth Director 10 Feb 2025 1,806,317 0 - - Series A convertible preferred stock
Bruce Booth Director 10 Feb 2025 1,051,051 0 - - Series Seed convertible preferred stock
Bruce Booth Director Purchase of securities on an exchange or from another person at price $ 18.00 per share. 10 Feb 2025 60,000 807,727 - 18 1,080,000 Common Stock
Bruce Booth Director 10 Feb 2025 747,727 747,727 - - Common Stock
Bruce Booth Director 10 Feb 2025 2,886,293 2,886,293 - - Common Stock
Bruce Booth Director 10 Feb 2025 1,092,504 0 - - Series C convertible preferred stock
Bruce Booth Director 10 Feb 2025 61,463 0 - - Series C convertible preferred stock
Peter A. Thompson Director 10 Feb 2025 2,560,951 0 - - Series B convertible preferred stock
Peter A. Thompson Director 10 Feb 2025 2,048,760 0 - - Series C convertible preferred stock
Peter A. Thompson Director Purchase of securities on an exchange or from another person at price $ 18.00 per share. 10 Feb 2025 550,000 3,704,959 - 18 9,900,000 Common Stock
Elena H. Ridloff CFO & Head of Corp. Dev. Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Feb 2025 157,820 157,820 - - Stock Option (Right to Buy)
Michael Cloonan Director, President & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Feb 2025 450,252 450,252 - - Stock Option (Right to Buy)
Joanne Louise Viney Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Feb 2025 39,919 39,919 - - Stock Option (Right to Buy)
Marcella Kuhlman Ruddy Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Feb 2025 39,919 39,919 - - Stock Option (Right to Buy)
Charlotte McKee Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Feb 2025 148,536 148,536 - - Stock Option (Right to Buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters